A MultiCenter, Open-Label Phase 1 Study of DS-1205c in Combination with GEFITINIB in SUBJECTS with Metastatic or Unresectable egfr mutant Non Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs DS 1205 (Primary) ; Gefitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Daiichi Sankyo Company
- 18 Oct 2018 according to a media release, first patient has been dosed in this first-in-human study.
- 24 Aug 2018 Status changed from not yet recruiting to recruiting.
- 11 Jul 2018 New trial record